No connection

Search Results

ABBV vs APLM

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
APLM
Apollomics, Inc.
BEARISH
Price
$19.90
Market Cap
$42.7M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ABBV
163.63
APLM
--
Forward P/E
ABBV
15.42
APLM
-30.62
P/B Ratio
ABBV
-146.66
APLM
-4.99
P/S Ratio
ABBV
6.5
APLM
6.15
EV/EBITDA
ABBV
15.27
APLM
-0.78

Profitability

Gross Margin
ABBV
71.46%
APLM
100.0%
Operating Margin
ABBV
35.5%
APLM
-124.8%
Profit Margin
ABBV
4.0%
APLM
0.0%
ROE
ABBV
137.96%
APLM
-380.13%
ROA
ABBV
9.59%
APLM
-72.29%

Growth

Revenue Growth
ABBV
9.1%
APLM
380.8%
Earnings Growth
ABBV
-88.7%
APLM
--

Financial Health

Debt/Equity
ABBV
--
APLM
--
Current Ratio
ABBV
0.72
APLM
0.97
Quick Ratio
ABBV
0.47
APLM
0.91

Dividends

Dividend Yield
ABBV
3.05%
APLM
--
Payout Ratio
ABBV
490.15%
APLM
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
APLM BEARISH

APLM's Piotroski F-Score of 3/9 indicates weak financial health, with significant red flags in profitability, cash flow, and leverage. The company exhibits extreme negative profitability metrics, including a -124.8% operating margin and -380.13% ROE, despite a 380.8% YoY revenue growth. With no Altman Z-Score available and a current ratio of 0.97, liquidity concerns persist. The stock trades at a high Price/Sales of 6.15 and a negative forward P/E of -30.62, suggesting valuation is driven by speculative growth expectations rather than fundamentals. The 52-week price range of $3.66 to $42.12 reflects extreme volatility, and the 5-year return of -98.0% underscores long-term underperformance.

Strengths
380.8% YoY revenue growth indicates strong top-line expansion
100.0% gross margin suggests efficient cost structure on sales
Recent 6-month return of +191.4% shows strong short-term momentum
Risks
Piotroski F-Score of 3/9 signals severe financial distress and weak operational health
Negative ROE (-380.13%) and ROA (-72.29%) indicate deep losses relative to equity and assets
Operating margin of -124.8% reflects unsustainable cost structure or one-time expenses

Compare Another Pair

ABBV vs APLM: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and Apollomics, Inc. (APLM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile